Sessa Capital Im LP Has Trimmed Bristol Myers Squibb Co (BMY) Holding by $274.33 Million; As Performant Finl (PFMT) Market Valuation Declined, Mill Road Capital Management Upped Holding

August 10, 2018 - By Billy Entrekin

Bristol-Myers Squibb Company (NYSE:BMY) Logo

Sessa Capital Im Lp decreased its stake in Bristol Myers Squibb Co (BMY) by 96.14% based on its latest 2018Q1 regulatory filing with the SEC. Sessa Capital Im Lp sold 4.35M shares as the company’s stock declined 23.11% with the market. The institutional investor held 175,000 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $11.07M, down from 4.53M at the end of the previous reported quarter. Sessa Capital Im Lp who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $97.34 billion market cap company. The stock increased 0.20% or $0.12 during the last trading session, reaching $59.65. About 104,865 shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 2.98% since August 10, 2017 and is downtrending. It has underperformed by 15.55% the S&P500. Some Historical BMY News: 17/04/2018 – Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting; 26/04/2018 – Bristol-Myers’ cancer drug Opdivo fuels growth, but revenue falls short; 16/04/2018 – #AACR18 says there was an embargo break on $BMY that triggered the early release — not $BMY; 26/04/2018 – Opdivo Drives Bristol-Myers Growth — Earnings Review; 27/03/2018 – Breckenridge: Entecavir a Generic Version of Baraclude Tablets by Bristol-Myers Squibb; 17/04/2018 – BRISTOL-MYERS SQUIBB CO BMY.N : MORGAN STANLEY CUTS TO EQUAL-WEIGHT FROM OVERWEIGHT; 17/05/2018 – Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Phase 2 Second Line Pancreatic Cancer Study; 02/05/2018 – Bristol-Myers Squibb and Biogen Are the Pharmas Most Trusted by Doctors, Study Finds; 16/04/2018 – JANSSEN ANNOUNCES WORLDWIDE DEVELOPMENT & COMMERCIALIZATION COLLABORATION WITH BRISTOL-MYERS TO ADVANCE THERAPY FOR CARDIOVASCULAR DISEASES; 26/04/2018 – Bristol-Myers Cuts 2018 View To EPS $2.70-EPS $2.80

Mill Road Capital Management Llc increased its stake in Performant Finl Corp (PFMT) by 65.35% based on its latest 2018Q1 regulatory filing with the SEC. Mill Road Capital Management Llc bought 1.44 million shares as the company’s stock declined 20.71% with the market. The hedge fund held 3.63 million shares of the other consumer services company at the end of 2018Q1, valued at $10.90M, up from 2.20M at the end of the previous reported quarter. Mill Road Capital Management Llc who had been investing in Performant Finl Corp for a number of months, seems to be bullish on the $159.73 million market cap company. The stock increased 0.32% or $0.01 during the last trading session, reaching $3.11. About 50,361 shares traded. Performant Financial Corporation (NASDAQ:PFMT) has risen 0.45% since August 10, 2017 and is uptrending. It has underperformed by 12.12% the S&P500. Some Historical PFMT News: 04/05/2018 – PERFORMANT FINANCIAL – ON MAY 3, DOJ NOTIFIED U.S. COURT OF FEDERAL CLAIMS THAT DEPARTMENT OF EDUCATION TO CANCEL CONTRACT AWARDED TO UNIT ON JAN 11; 08/05/2018 – Performant Financial 1Q Rev $57M; 06/03/2018 – PERFORMANT FINANCIAL 4Q REV. $33.3M, EST. $30.2M (2 EST.); 06/03/2018 – Performant Financial Sees 2018 Rev $123M-$150M; 06/03/2018 – PERFORMANT FINANCIAL CORP SEES FULL YEAR 2018 REVENUE OF $123 TO $150 MLN; 06/03/2018 – PERFORMANT FINANCIAL CORP – QTRLY TOTAL REVENUES OF $33.3 MLN, COMPARED TO $33.8 MLN IN PRIOR YEAR; 06/03/2018 – PFMT SEES FY REV. $123M TO $150M, EST. $124.0M (2 EST.); 29/05/2018 – CallMiner Announces Eureka Coach to Provide Contact Center Optimization with Continuous Insight and Closed-Loop Case Management; 08/05/2018 – Performant Financial 1Q EPS 16c; 06/03/2018 – PERFORMANT FINANCIAL 4Q ADJ EPS 2C, EST. LOSS/SHR 3C (2 EST.)

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Forbes.com which released: “A Ramp Up In Opdivo And Eliquis Sales Will Drive Bristol-Myers Squibb’s Future Growth” on July 30, 2018, also Benzinga.com with their article: “Q2 Earnings Preview For Bristol-Myers Squibb” published on July 25, 2018, Seekingalpha.com published: “BeiGene launches late-stage study of tislelizumab in first-line lung cancer” on August 09, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on August 08, 2018 as well as Nasdaq.com‘s news article titled: “Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers …” with publication date: August 08, 2018.

Since April 30, 2018, it had 1 insider purchase, and 0 selling transactions for $249,948 activity.

Investors sentiment decreased to 0.83 in Q1 2018. Its down 0.11, from 0.94 in 2017Q4. It worsened, as 64 investors sold BMY shares while 573 reduced holdings. 111 funds opened positions while 418 raised stakes. 1.12 billion shares or 1.08% more from 1.11 billion shares in 2017Q4 were reported. Rhenman And Prtnrs Asset Mgmt holds 2.73% or 350,000 shares in its portfolio. Woodmont Invest Counsel Ltd Liability Corp reported 0.41% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Kepos LP stated it has 20,972 shares or 0.08% of all its holdings. First Mercantile Tru owns 0.83% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 62,855 shares. Kornitzer Management Ks, Kansas-based fund reported 201,340 shares. Pettyjohn Wood & White holds 6,625 shares. Bancorp Of Montreal Can stated it has 0.32% in Bristol-Myers Squibb Company (NYSE:BMY). Lincoln holds 0.03% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 14,652 shares. Aldebaran Inc has 0.5% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 11,888 shares. Lbmc Invest Advisors Ltd Liability owns 6,201 shares. Alpha Cubed Investments Ltd Liability holds 0.08% or 10,020 shares. Gradient Investments reported 8,549 shares stake. Reliance Of Delaware holds 55,266 shares or 0.54% of its portfolio. New South Capital Mngmt holds 8,312 shares or 0.01% of its portfolio. Guardian Invest holds 2.67% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 39,577 shares.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on October, 25. They expect $0.89 EPS, up 18.67% or $0.14 from last year’s $0.75 per share. BMY’s profit will be $1.45 billion for 16.76 P/E if the $0.89 EPS becomes a reality. After $1.01 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -11.88% negative EPS growth.

Among 22 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 1 Sell and 15 Hold. Therefore 27% are positive. Bristol-Myers Squibb Company had 90 analyst reports since July 28, 2015 according to SRatingsIntel. Hilliard Lyons downgraded the shares of BMY in report on Tuesday, September 12 to “Hold” rating. The rating was maintained by BMO Capital Markets on Monday, November 13 with “Sell”. BMO Capital Markets maintained it with “Sell” rating and $4700 target in Sunday, July 23 report. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by DZ Bank on Wednesday, February 28. BMO Capital Markets upgraded the stock to “Market Perform” rating in Friday, April 27 report. The company was downgraded on Thursday, August 11 by Berenberg. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Jefferies on Monday, October 16. The firm has “Buy” rating by Leerink Swann given on Thursday, July 27. Piper Jaffray maintained the stock with “Hold” rating in Thursday, October 26 report. As per Monday, June 5, the company rating was maintained by BMO Capital Markets.

Another recent and important Performant Financial Corporation (NASDAQ:PFMT) news was published by Globenewswire.com which published an article titled: “Performant Financial Corporation Announces Financial Results for Second Quarter 2018” on August 09, 2018.

Mill Road Capital Management Llc, which manages about $766.84 million and $125.38 million US Long portfolio, decreased its stake in Smtc Corp (NASDAQ:SMTX) by 408,283 shares to 374,816 shares, valued at $851,000 in 2018Q1, according to the filing.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts